⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZVRA News
Zevra Therapeutics, Inc. Common Stock
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
globenewswire.com
ZVRA
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
globenewswire.com
ZVRA
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
globenewswire.com
ZVRA
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
globenewswire.com
ZVRA
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
globenewswire.com
ZVRA
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ZVRA
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
globenewswire.com
ZVRA
Zevra Therapeutics, Inc. Announces CFO Transition
globenewswire.com
ZVRA
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
globenewswire.com
ZVRA
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
globenewswire.com
ZVRA